- WASHINGTON (Reuters) - Gilead Sciences Incs Truvada tablets appear safe and effective for reducing the risk of HIV infection, U.S. regulators said on Tuesday. (msnbc.com)
- WASHINGTON - Gilead Sciences (GILD) Truvada may prevent HIV infection among high-risk individuals, if used in combination with other health strategies, and is well-tolerated by individuals who have not contracted the virus that causes AIDS, U. (Silicon Valley)
- Should an HIV treatment become a prophylactic? Thats the question an FDA panel will address later this week, when it considers the data on forestalling HIV infection with Gilead Sciences ($GILD) Truvada. (FiercePharma)
- Gilead Sciences, Inc., produces the drug Truvada (emtricitabine/tenofovir disoproxil fumarate), which is already approved for use in treating some patients that already have AIDS. (Philadelphia Daily News)
- Research conducted by Gilead Sciences on Truvada, a landmark HIV prevention pill, now has the backing of the Food and Drug Administration. (KQED)
- FDA Panel Considers HIV Drug for New Use (WSJ): Gilead Sciences has asked the Food and Drug Administration to consider approving its HIV treatment Truvada as a preventive medicine—a potential first—that could keep people from contracting the virus. (Wall Street Journal)
- Want to see more news summaries? Sign up for AHIP Solutions SmartBrief AHIP Solutions SmartBrief is a FREE, daily email newsletter that summarizes the days top industry news from hundreds of sources. (SmartBrief)
- Sales of HIV drugs Atripla grew 19 percent from last year, and Truvada by 13 percent. (NASDAQ)
- Truvada Sales of Truvada increased 13 percent to $758.3 million for the first quarter of 2012, up from $673.1 million for the first quarter of 2011, reflecting sales growth of 17 percent in the U.S. and 8 percent in Europe. (Seekingalpha.com)
Tuesday, May 8, 2012
Truvada
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment